© 2023 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest Conference Articles
Dr Michael Chiang: How the National Eye Institute Is Building Confidence in Ophthalmology Biosimilars
Skylar Jeremias
January 15 2023
AAO: American Academy of Ophthalmology
Michael Chiang, MD, director of the National Eye Institute, discusses how his team is working to instill greater confidence in ophthalmology biosimilars among wary ophthalmologists.
AAO Posters Investigate Ranibizumab Biosimilar Impact on Patient Outcomes
Skylar Jeremias
November 2 2022
AAO: American Academy of Ophthalmology
Two studies presented at the American Academy of Ophthalmology (AAO) annual meeting in Chicago, Illinois, demonstrated the impact that a ranibizumab biosimilar (SB11; Byooviz) can have on patient outcomes.
Policy Harmonization, Clarification Could Aid Biosimilar Uptake Efforts
Skylar Jeremias
September 23 2022
Realigning definitions and policies across regulatory agencies and developing a better understanding of how different stakeholders approach biosimilars could help get more patients and providers on board with using biosimilars, according to panelists at the DIA Biosimilars Conference.
Rituximab Biosimilars Prove Effective in Large B-Cell Lymphoma
Skylar Jeremias
July 14 2022
Abstracts from the European Hematology Association Congress 2022 confirmed comparable safety and effectiveness profiles between 2 rituximab biosimilars and the reference product (Rituxan) in patients with large B-cell lymphoma.
ASCO Studies Assess Biosimilar Substitution, Adoption in Oncology Practices
Skylar Jeremias
June 16 2022
Abstracts from the American Society of Clinical Oncology (ASCO) annual meeting took a look at the impact biosimilar substitution and increased biosimilar adoption had on spending within practices participating in value-based payment models and the Oncology Care Model.
